Minerva Neurosciences

OverviewSuggest Edit

Minerva Neurosciences is a clinical-stage biopharmaceutical company which focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The Company's lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia. It also offers a number of product candidates for treating primary insomnia, major depressive disorder and Parkinson's disease.

TypePublic
Founded2007
HQWaltham, MA, US
Websiteminervaneurosciences.com

Latest Updates

Employees (est.) (Dec 2018)13(+9%)
Revenue (FY, 2019)$0
Share Price (Jan 2021)$2.7
Cybersecurity ratingAMore

Key People/Management at Minerva Neurosciences

Remy Luthringer

Remy Luthringer

Executive Chairman & Chief Executive Officer
Geoff Race

Geoff Race

Executive Vice President, Chief Financial Officer and Chief Business Officer
Michael Davidson

Michael Davidson

Chief Medical Officer
Joseph Reilly

Joseph Reilly

Senior Vice President and Chief Operating Officer
Frederick Ahlholm

Frederick Ahlholm

Senior Vice President and Chief Accounting Officer
Jay Saoud

Jay Saoud

Senior Vice President, Head of Research and Development
Show more

Minerva Neurosciences Office Locations

Minerva Neurosciences has an office in Waltham
Waltham, MA, US (HQ)
1601 Trapelo Rd #286
Show all (1)

Minerva Neurosciences Financials and Metrics

Minerva Neurosciences Revenue

USD

Net income (Q3, 2020)

(8.1m)

EBIT (Q3, 2020)

(8.1m)

Market capitalization (15-Jan-2021)

115.6m

Closing stock price (15-Jan-2021)

2.7

Cash (30-Sept-2020)

32.5m

EV

83.3m
Minerva Neurosciences's current market capitalization is $115.6 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

12.0m7.6m9.8m10.9m16.8m17.7m

R&D expense

42.9m18.5m20.4m30.3m34.9m58.1m

Operating expense total

54.9m26.1m30.2m41.2m51.7m75.9m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

41.2m

General and administrative expense

3.1m2.4m1.9m1.8m1.9m2.4m2.3m2.4m2.9m2.6m2.5m4.3m3.9m4.1m4.7m4.6m4.6m4.2m5.9m3.5m

R&D expense

14.6m24.7m4.0m4.5m3.8m5.4m2.7m5.9m7.6m7.1m9.0m8.4m9.1m8.4m11.6m8.3m9.7m8.1m5.8m4.6m

Operating expense total

17.6m27.2m5.9m6.3m5.7m7.8m5.0m8.2m10.5m9.7m11.4m12.7m12.9m12.4m16.3m12.9m14.3m12.3m11.7m8.1m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

18.5m14.3m83.0m26.1m50.2m21.4m

Accounts Receivable

370.0k577.0k

Prepaid Expenses

1.3m1.9m1.2m

Inventories

84.0k1.2m803.2k
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(56.9m)(27.1m)(31.0m)(31.5m)(50.2m)(72.2m)

Depreciation and Amortization

33.9k17.3k16.5k11.1k17.5k17.5k

Inventories

939.0k(400.0k)372.7k

Accounts Payable

368.7k718.8k107.8k(32.7k)364.0k517.3k
USDQ2, 2014

Financial Leverage

1.8 x
Show all financial metrics

Minerva Neurosciences Operating Metrics

FY, 2016

Phase I Trials Products

1

Phase II Trials Products

3

Pre-Clinical Phase Products

1
Show all operating metrics

Minerva Neurosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Minerva Neurosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Minerva Neurosciences Online and Social Media Presence

Embed Graph

Minerva Neurosciences News and Updates

NERV DEADLINE: Zhang Investor Law Reminds Investors with Losses of the Deadline in Securities Class Action Lawsuit Against Minerva Neurosciences, Inc. – NERV

NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of  Minerva Neurosciences, Inc. (NASDAQ: NERV)  between May 15, 2017 and November 30, 2020, inclusive (the “Class Period”).

SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Minerva Neurosciences, Inc.– NERV

NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NERV) from May 15, 2017 through November 30, 2020, inclusive (the “Class Period”). The lawsuit see…

Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Vir…

Minerva Neurosciences to Report Third Quarter 2020 Financial Results and Business Updates on November 2, 2020

Management to host conference call Management to host conference call

Minerva Neurosciences to Present at Citi's 15th Annual BioPharma Virtual Conference

WALTHAM, Mass., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in Citi's 15th Annu…

Minerva Neurosciences Reports Second Quarter 2020 Financial Results and Business Updates

WALTHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the quarte…
Show more

Minerva Neurosciences Blogs

Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates

Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates Content Import Mon, 11/02/2020 - 07:30 Minerva Neurosciences Reports Third Quarter 2020 Financial Results And Business Updates November 02, 2020 This release is a backfill…

Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference

Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference Content Import Wed, 09/09/2020 - 08:30 Minerva Neurosciences to Present at H.C. Wainwright 22nd Annual Global Investment Conference September 09, 2020 This release is…

Minerva Neurosciences to Present at JMP Securities CNS Forum

WALTHAM, Mass. , Aug. 13, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the JMP Securities

Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020

Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020 Content Import Mon, 07/27/2020 - 08:01 Minerva Neurosciences to Report Second Quarter 2020 Financial Results and Business Updates on August 3, 2020 July 27, 2020 …

Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)

Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexant Corporate focus now on lead product, roluperidone, in Phase 3 development WALTHAM, Mass.

REVISED WEBCAST & CALL INFORMATION: Minerva Neurosciences to Hold Webcast and Call With Key Opinion Leaders to Present Additional Analyses From Phase 3 Trial of Roluperidone (MIN-101) for Treatment of Negative Symptoms in Schizophrenia

WALTHAM, Mass. , June 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announced today that the company will hold a webcast on Friday, June 5, 2020
Show more

Minerva Neurosciences Frequently Asked Questions

  • When was Minerva Neurosciences founded?

    Minerva Neurosciences was founded in 2007.

  • Who are Minerva Neurosciences key executives?

    Minerva Neurosciences's key executives are Remy Luthringer, Geoff Race and Michael Davidson.

  • How many employees does Minerva Neurosciences have?

    Minerva Neurosciences has 13 employees.

  • Who are Minerva Neurosciences competitors?

    Competitors of Minerva Neurosciences include ITBMed, CNS Healthcare and Ncardia.

  • Where is Minerva Neurosciences headquarters?

    Minerva Neurosciences headquarters is located at 1601 Trapelo Rd #286, Waltham.

  • Where are Minerva Neurosciences offices?

    Minerva Neurosciences has an office in Waltham.

  • How many offices does Minerva Neurosciences have?

    Minerva Neurosciences has 1 office.